NEUROGENE INC (NGNE)
(Delayed Data from NSDQ)
$31.01 USD
-0.06 (-0.19%)
Updated Jun 21, 2024 04:00 PM ET
After-Market: $31.04 +0.03 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
NGNE 31.01 -0.06(-0.19%)
Will NGNE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for NGNE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for NGNE
Neurogene Releases Updated Corporate Presentation Online
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Neurogene negative reaction to competitor data 'overblown,' says William Blair
TD Cowen Keeps Their Buy Rating on Neurogene (NGNE)
Buy Rating Maintained for Neurogene Amid Promising Efficacy of NGN-401 Treatment